What is Crescent Biopharma, Inc. (CBIO) stock price today?

Crescent Biopharma, Inc. (CBIO) currently trades at $22.37 per share. The stock has a market capitalization of $755.46M and a P/E ratio of —x.

Is CBIO stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Crescent Biopharma, Inc. has a Smart Value Score of 25/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Crescent Biopharma, Inc.'s revenue and earnings?

Crescent Biopharma, Inc. has trailing twelve-month (TTM) revenue of $10.84M with profit margins of 0.00%. Earnings per share (EPS) is $-12.81.

CBIO

Crescent Biopharma, Inc.

NASDAQ: CBIO · HEALTHCARE · BIOTECHNOLOGY

$22.37

+6.83% today

Updated 2026-04-30

Market cap

$755.46M

P/E ratio

—

P/S ratio

69.67x

EPS (TTM)

$-12.81

Dividend yield

—

52W range

$9 – $29

Volume

0.2M

Market cap

$755.46M

P/E ratio

—

P/S ratio

69.67x

EPS (TTM)

$-12.81

Dividend yield

—

52W range

$9 – $29

Volume

0.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

6.0

Growth

5.0

Quality

C+

2.5

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$29.29

+30.93%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy8 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-9.08M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$75000.00	$10000.00	—	$10.84M	$10.84M
Net income	$-46.69M	$-36.90M	$-71.47M	$-149.94M	—
EPS	—	—	—	—	$-12.81
Free cash flow	$-46.54M	$-34.90M	$-31.11M	$-72.45M	$-9.08M
Profit margin	-62,251.74%	-368,994.20%	—	-1,382.72%	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-01-07	ZHANG, PING	Buy	100,000	—
2026-01-07	CHEN, RUOYU	Buy	50,000	—
2025-08-18	WENG, DAN	Buy	52,000	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
CBIO	$755.46M	25	6.0	2.5	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Crescent Biopharma, Inc. trades at $22.37. Our Smart Value Score of 25/100 indicates the stock is weak. TTM revenue stands at $10.84M.

Frequently asked questions

What is Crescent Biopharma, Inc.'s stock price?

Crescent Biopharma, Inc. (CBIO) trades at $22.37.

Is Crescent Biopharma, Inc. overvalued?

Smart Value Score 25/100 (Grade F, Strong Sell).

What is the price target of Crescent Biopharma, Inc. (CBIO)?

The analyst target price is $29.29, representing +30.9% upside from the current price of $22.37.

What is Crescent Biopharma, Inc.'s revenue?

TTM revenue is $10.84M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

crescentbiopharma.com

Quick metrics

P/S ratio69.67x

ROE-160.70%

Beta—

50D MA$14.89

200D MA$13.13

Shares out0.03B

Float0.01B

Short ratio—

Avg volume0.2M

Performance

1 week-9.80%

1 month+15.79%

3 months+133.26%

YTD+88.62%

1 year—

3 years—

5 years—

Compare

CBIO vs LLY →CBIO vs JNJ →CBIO vs ABBV →Stock screener →